Drug intelligence / Profile preview

ibandronate + zoledronic acid

Development stage: Preclinical
Lead developer: Null
Modality: Small Molecules
Administration: Intravenous

Overview

Combination of two nitrogen-containing bisphosphonates (ibandronate and zoledronic acid) that inhibit osteoclast function and prevent bone resorption. Both drugs bind to hydroxyapatite in bone and inhibit farnesyl diphosphate synthase in the mevalonate pathway, leading to disruption of GTP-binding proteins and osteoclast apoptosis. The combination has shown synergistic effects in some studies, particularly when used with anticancer drugs.

Targets

FDPS (Farnesyl pyrophosphate synthase)ABCC9

Beyond the preview

Go deeper on ibandronate + zoledronic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibandronate + zoledronic acid.

Explore the full profile